Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hemostemix Inc (OP: HMTXF ) 0.0301 UNCHANGED Streaming Delayed Price Updated: 12:56 PM EDT, Aug 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Hemostemix Inc Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board September 27, 2022 Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... Via Newsfile Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board September 20, 2022 Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... Via Newsfile Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board September 16, 2022 Calgary, Alberta--(Newsfile Corp. - September 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is... Via Newsfile Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board September 15, 2022 Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board September 14, 2022 Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased... Via Newsfile Hemostemix Announces Its Presentation to the Emerging Growth Conference September 14, 2022 Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")... Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc. September 13, 2022 Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased... Via Newsfile Hemostemix Announces Closing of $2,750,000 April 26, 2022 Hemostemix Announces Closing of $2,750,000 - IssueWire Via IssueWire Topics Intellectual Property Exposures Intellectual Property Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed April 13, 2022 Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed - IssueWire Via IssueWire Topics Intellectual Property Lawsuit Exposures Financial Intellectual Property Legal Your Fountain of Youth Trademarked by Hemostemix Inc. March 03, 2022 Your Fountain of Youth Trademarked by Hemostemix Inc. - IssueWire Via IssueWire Topics Intellectual Property Exposures Intellectual Property Hemostemix Announces Closing of UNIT Private Placement March 03, 2022 Hemostemix Announces Closing of UNIT Private Placement - IssueWire Via IssueWire Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday December 14, 2021 Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... Via Benzinga Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years September 14, 2021 Calgary, Alberta--(Newsfile Corp. - September 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased... Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results July 06, 2021 Calgary, Alberta--(Newsfile Corp. - July 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Peter Lacey Increases His Investment in Hemostemix Inc. June 21, 2021 Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture June 11, 2021 Calgary, Alberta--(Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased... Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list April 23, 2021 Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company")... Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd. April 08, 2021 Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) ("Hemostemix" or the... Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.